Studies on the contribution of the F1 capsule-associated plasmid pFra to the virulence of Yersinia pestis.
Explore the source record for details and available documents.
Animals↗
Biomedical subjects
S L Welkos
Publications and source records attributed to S L Welkos.
Construction of defined F1 negative mutants of virulent Yersinia pestis.
Explore the source record for details and available documents.
Animals↗
Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pX02 and chromosome in strain-dependent virulence.
The toxin-encoding plasmid pX01 and capsule-associated plasmid pX02 are required for full virulence of Bacillus anthracis in some animals. However, the non-toxigenic pX01-cured derivatives of certain anthrax strains are not completely attenuated for mice, and their virulence is strain-dependent. The strain-related differences were partially associated with plasmid pX02 as demonstrated by pX02 transductants of the attenuated vaccine strain UM23-1 cured of pX01. To determine the virulence of non-toxigenic variants of virulent strains, we isolated pX01- derivatives of the Vollum 1B strain and the more 'vaccine-resistant' Ames strain which carried pX02 from either Ames or Vollum 1B. The 50% lethal dose (LD50) values of the derivatives of both strains which carried the Ames pX02 were not significantly different from the LD50s of the pX01+ pX02+ strains (and were lower than those of pX01+ pX02- strains). pX02+ derivatives of strain UM23-1 were less virulent than the comparable Ames and Vollum 1B strain derivatives, emphasizing a role for chromosomal loci in the virulence of the latter two strains. Non-toxigenic isolates which carried the Ames pX02 were more virulent for CBA/J mice than those with Vollum 1B pX02, and the differences were mouse strain-dependent. The pX01- pX02+ strains multiplied and achieved high concentrations systemically.
Animals↗
Postexposure prophylaxis against experimental inhalation anthrax.
Inhalation anthrax is a rare disease that is almost invariably fatal. This study determined whether a prolonged course of postexposure antibiotics with or without vaccination would protect monkeys exposed to a lethal aerosol dose of Bacillus anthracis when the antibiotic was discontinued. Beginning 1 day after exposure, groups of 10 animals were given penicillin, ciprofloxacin, doxycycline, doxycycline plus vaccination, vaccination alone, or saline. Antibiotics were administered for 30 days and then discontinued. Vaccine was given on days 1 and 15. Two animals died of causes other than anthrax and were not included in the statistical analysis. Nine of 10 controls and 8 of 10 animals given only vaccine died. Each antibiotic regimen completely protected animals while on therapy and provided significant long-term protection upon discontinuance of the drug (penicillin, 7 of 10 survived, P < .02; ciprofloxacin, 8 of 9 survived, P < .002; doxycycline, 9 of 10 survived, P < .002; doxycycline plus vaccination, 9 of 9 survived, P < .0002). Protection against rechallenge was provided by combining postexposure antibiotic treatment with vaccination.
Aerosols↗
Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants.
The protective efficacy of immunization against anthrax with Bacillus anthracis protective antigen (PA) combined with different adjuvants was tested in Hartley guinea pigs and CBA/J and A/J mice. Adjuvant components derived from microbial products that were tested included threonyl-muramyl dipeptide (threonyl-MDP); monophosphoryl lipid A (MPL); trehalose dimycolate (TDM); and the delipidated, deproteinized, cell wall skeleton (CWS) from either Mycobacterium phlei or the BCG strain of Mycobacterium bovis. Non-microbially derived adjuvants tested included aluminum hydroxide and the lipid amine CP-20,961. In guinea pigs, all adjuvants and adjuvant mixtures enhanced antibody titers to PA as well as survival after a parenteral challenge of virulent B. anthracis Ames spores. In contrast, PA alone or combined with either aluminum hydroxide or CP-20,961 failed to protect mice. Vaccines containing PA combined with threonyl-MDP or MPL-TDM-CWS protected a majority of female CBA/J mice. Statistical analysis of survival data in the guinea pigs indicated that PA-MPL-CWS and PA-MPL-TDM-CWS were more efficacious than the currently licensed human anthrax vaccine.
Adjuvants, Immunologic↗
Plasmid-associated virulence factors of non-toxigenic (pX01-) Bacillus anthracis.
The anthrax toxins and capsule, encoded by plasmids pX01 and pX02, respectively, are the only known virulence factors of Bacillus anthracis and are considered essential for full virulence. Some B. anthracis strains cured of pX01, such as delta Ames-1, remained virulent for mice. The virulence was partially mediated by pX02, as determined by phage transduction. pX02 plasmids from the delta Ames-1 and Pasteur strains were mutagenized with transposon Tn917 to identify loci associated with virulence. The capsule phenotype, virulence and pX02 restriction pattern of the insertion mutants were characterized. Two mutants that produced no detectable capsule were avirulent. One had a deletion of more than 20 kb, which included the structural genes required for capsule synthesis (cap); the second had an insertion outside of cap. Two mutants with reduced encapsulation had insertions at different sites outside cap and were less virulent, whereas one that was normally encapsulated, but had a high rate of pX02 curing, was unaltered in virulence. Mutants that produced greater amounts of capsule than the parental strain were more virulent, and a few that produced wild-type levels of capsule were less virulent.
Animals↗
Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals.
We previously described the cloning and expression of the protective antigen (PA) gene of Bacillus anthracis in both vaccinia virus and a baculovirus. The antigenicity of the PA products was characterized. PA expressed by the recombinant vaccinia viruses elicited a partial protective immune response against a lethal B. anthracis spore challenge in guinea pigs and mice. The WR strain vaccinia virus recombinant (WR-PA) protected 60% of male mice and 50% of guinea pigs. WR-PA elicited high anti-PA antibody titers in mice but not in guinea pigs. Connaught strain vaccinia virus recombinants failed to protect any immunized animals. PA purified from baculovirus recombinant-infected cultures plus adjuvant partially protected male CBA/J mice and completely protected female Hartley guinea pigs from challenge. Both the recombinant and nonrecombinant PA preparations combined with adjuvant elicited high anti-PA antibody titers in Hartley guinea pigs and CBA/J mice. These data demonstrate that the recombinant baculovirus- and vaccinia virus-produced PAs were immunogenic in both guinea pigs and mice, that the baculovirus-PA recombinant was a useful source of immunogenic PA, and that vaccinia virus-PA recombinants may be feasible live anthrax vaccine candidates worthy of consideration for further development as live vaccines.
Animals↗
Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen.
The safety and efficacy of five prototype, live anthrax vaccines were studied in Hartley guinea pigs and CBA/J and A/J mice. Two of the strains, Bacillus anthracis FD111 and FD112, are Aro- mutants derived by Tn916 mutagenesis of B. anthracis UM23-1. Bacillus subtilis PA1 and PA2 contain a recombinant plasmid, pPA101 or pPA102, respectively, that carries the gene from B. anthracis encoding synthesis of protective antigen (PA). The final strain, B. subtilis PA7, was isolated in this study from B. subtilis DB104 transformed with pPA101. All five strains were less virulent in guinea pigs and A/J and CBA/J mice than the toxinogenic, nonencapsulated B. anthracis veterinary vaccine Sterne strain. A/J and CBA/J inbred mice represent strains that are innately susceptible and resistant, respectively, to the Sterne strain. These differences in susceptibility are due to differences in ability to produce complement component 5. In guinea pigs, immunization with PA1 or PA2 vegetative cells or PA7 spores protected greater than or equal to 95% from an intramuscular spore challenge with the virulent, "vaccine-resistant" B. anthracis Ames strain. Strain PA2 vegetative cells and strain PA7 spores were as effective as the Sterne strain in Sterne-resistant CBA/J mice, protecting 70% of the mice from Ames strain spore challenge. Immunization with FD111 or FD112 vegetative cells fully protected guinea pigs from challenge. Immunization with FD111 cells protected up to 100% of CBA/J mice and up to 70% of A/J mice.
Animals↗
Resistance to the Sterne strain of B. anthracis: phagocytic cell responses of resistant and susceptible mice.
Inflammatory responses were compared in vivo, and host phagocytic cell functions compared in vitro, of mice resistant (CBA/J) and susceptible (A/J) to lethal infection with the Sterne strain of Bacillus anthracis. Polymorphonuclear leukocyte (PMN) and macrophage responses at the initial site of infection were slower in A/J mice than in CBA/J mice. Whereas in A/J mice, the number of PMN ultimately responding to infection was equal to, or greater than, that in CBA/J mice, fewer macrophages accumulated. A/J mice failed to clear relatively low doses of the organisms and died. In vitro, chemotactic responses to both serum- and bacteria-derived attractants were similar for macrophages from A/J and CBA/J mice but were reduced for PMN from A/J mice. PMN and macrophages from the two mouse strains phagocytosed and killed spores in vitro to a similar extent, although killing by A/J PMN could be blocked by prior uptake of large numbers of killed spores. Thus susceptibility to lethal infection with Sterne strain correlated with the delayed influx (PMN) and reduced accumulation (macrophages) of phagocytes at the initial site of infection, but not with defective in vitro uptake or killing of spores.
Animals↗
Sequence and analysis of the DNA encoding protective antigen of Bacillus anthracis.
The nucleotide sequence of the protective antigen (PA) gene from Bacillus anthracis and the 5' and 3' flanking sequences were determined. PA is one of three proteins comprising anthrax toxin; and its nucleotide sequence is the first to be reported from B. anthracis. The open reading frame (ORF) is 2319 bp long, of which 2205 bp encode the 735 amino acids of the secreted protein. This region is preceded by 29 codons, which appear to encode a signal peptide having characteristics in common with those of other secreted proteins. A consensus TATAAT sequence was located at the putative -10 promoter site. A Shine-Dalgarno site similar to that found in genes of other Bacillus sp. was located 7 bp upstream from the ATG start codon. The codon usage for the PA gene reflected its high A + T (69%) base composition and differed from those of genes for bacterial proteins from most other sequences examined. The TAA translation stop codon was followed by an inverted repeat forming a potential termination signal. In addition, a 192-codon ORF of unknown significance, theoretically encoding a 21.6-kDa protein, preceded the 5' end of the PA gene.
Amino Acid Sequence↗
Recent advances in the development of an improved, human anthrax vaccine.
Human anthrax vaccines currently licensed in the United States and Western Europe consist of alum-precipitated or aluminum hydroxide-adsorbed supernatant material from fermentor cultures of toxigenic, nonencapsulated strains of Bacillus anthracis. These vaccines have several drawbacks, including the need for frequent boosters, the apparent inability to protect adequately against certain strains of B. anthracis, and occasional local reactogenicity. Studies are being undertaken to develop an improved human anthrax vaccine which is safe and efficacious, and which provides long-lasting immunity. Aspects being studied include the identification of antigens and epitopes responsible for eliciting protective immunity, the mechanisms of resistance to anthrax infection, the role of specific antibody in resistance, the differences in immunity elicited by living and chemical vaccines, the potential of new adjuvants to augment immunity, and the feasibility of developing safe vaccine strains having mutationally altered toxin genes. Both living and non-living (chemical) prototype vaccines are being developed and tested.
Anthrax↗
Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice.
The efficacy and mechanisms of protection of two live vaccines and of a protective antigen (PA) vaccine against Bacillus anthracis were studied in inbred mice. Mice that differed in their natural resistance to killing by Sterne, a non-encapsulated, toxigenic vaccine strain of B. anthracis, were used. Vaccination with live Sterne spores protected Sterne-resistant mice against challenge with the virulent Vollum 1B (V1B) strain of B. anthracis, but only at doses of Sterne greater than or equal to 0.1 50% lethal dose. The live B. subtilis recombinant strain PA2, which produces the PA component of anthrax toxin, fully protected (CBA/J) or partially protected (BALB/cJ) Sterne-resistant mice against V1B. Neither immunization with the cell-free PA vaccine nor passive administration of anti-PA antiserum protected Sterne-resistant mice against V1B. Sterne-susceptible A/J mice were not protected against V1B by either live vaccine or by the PA vaccine. However, immunization with strain PA2 induced anti-PA antibody and protected A/J mice against Sterne. A/J mice passively treated with antitoxin antibodies also survived Sterne, and survivors were then partially protected against V1B. Thus, immunity to Sterne correlated with an effective anti-PA response. Immunity to fully virulent V1B also required PA but may involve mechanisms in addition to humoral immunity.
Animals↗
Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis.
The pathogenesis of lethal infection by the nonecapsulated, toxigenic Sterne strain of Bacillus anthracis and the genetic basis of resistance were characterized in mice. Lethal doses of Sterne spores produced disease in susceptible mice similar to that caused by toxigenic and encapsulated B. anthracis. At the inoculation site, the mice developed an edematous exudate with large concentrations of bacilli and toxin. In the susceptible A/J strain, lethal infection was accompanied by systemic invasion and serum anthrax toxin levels increased in parallel with systemic bacterial concentrations and with the mortality rate. Host resistance to Sterne infection was associated with the ability to synthesize the complement component 5 (C5). All Sterne-resistant mouse strains had a functional gene (Hc) encoding C5, whereas susceptible mice were deficient in C5. A/J mice could be passively protected from lethal challenge by C5-positive serum but not by serum from C5-negative congenic mice. Also resistance was linked to production of C5 in individual backcross (97%) and F2 (98%) mice. The distribution pattern for recombinant inbred mice was consistent with a major role in host resistance of Hc or a closely linked locus, although other genes probably contribute. This mouse model will be useful in characterizing the pathogenesis of anthrax and testing the safety and efficacy of new anthrax vaccines.
Animals↗
Transposon Tn916 mutagenesis in Bacillus anthracis.
Mutagenesis of Bacillus anthracis by the streptococcal tetracycline resistance transposon Tn916 is described. Tn916 was transferred from Streptococcus faecalis DS16C1 to B. anthracis VNR-1 by conjugation in a standard filter mating procedure. Tetracycline-resistant (Tcr) transconjugants were obtained at a frequency of 1.6 X 10(-8) per donor CFU. When donor and recipient cells were treated with nafcillin before conjugation, the frequency was increased nearly 10-fold. Nafcillin pretreatment of donor and recipient strains was used in all subsequent conjugation experiments. S.faecalis CG110, containing multiple chromosomal insertions of Tn916, transferred the transposon to B. anthracis VNR-1 at a frequency of 9.3 x 10(-5). A Tcr B. anthracis transconjugant, strain VNR-1-tet-1, transferred Tn916 to B. anthracis UM23-1 and Bacillus subtilis BST1 at frequencies of 2.1 x 10(-4) and 5.8 X 10(-6), respectively. The transfer of Tn916 occurred only on membrane filters, since no Tcr transconjugants were obtained when strains VNR-1-tet-1 and UM23-1 were mixed and incubated in broth culture. The presence of the Tn916-associated tetM gene in Tcr B. anthracis and B. subtilis transconjugants was confirmed in hybridization experiments by using a 5-kilobase-pair DNA fragment containing the tetM gene as a probe. Of 3,000 B. anthracis UM23-1 Tcr transconjugants tested, 21 were phenylalanine auxotrophs and 2 were auxotrophic for phenylalanine, tyrosine, and tryptophan.
Bacillus anthracis↗
Differences in susceptibility of inbred mice to Bacillus anthracis.
Animal species differ in their resistance both to infection by Bacillus anthracis and to anthrax toxin. A mouse model was developed to study the basis of the host differences and the pathogenesis of infection. When mice were infected with the virulent B. anthracis strain Vollum 1B, low 50% lethal dose (LD50) values (5 to 30 spores) were found for all 10 strains of inbred mice tested. However, analysis of time-to-death data revealed significant differences among the strains, which could be divided into three groups: most susceptible (A/J and DBA/2J); least susceptible (CBA/J, BALB/cJ, and C57BR/cdJ); and intermediate (the remaining five strains). In contrast, the mice were distinctly susceptible or resistant to lethal infection by the toxigenic, nonencapsulated Sterne vaccine strain. The LD50 for the susceptible A/J and DBA/2J mice was approximately 10(3) spores of the Sterne strain, whereas the remaining eight relatively resistant strains were killed only by 10(6) or more spores. F1 hybrid and backcross studies suggested that resistance to the Sterne strain is determined by a single dominant gene or gene complex. Mice lethally infected with B. anthracis showed an acute course of infection, characterized by extensive gelatinous edema and large concentrations of bacilli in the blood and organs (e.g., 10(9) CFU/g of spleen). The susceptibility of A/J and CBA/J mice to intravenously injected anthrax toxin components appeared to differ from their susceptibility to infection. The toxin LD50 values for both strains were similar. However, CBA/J mice died sooner than did A/J mice, with mean time to death of 0.9 and 3.7 days, respectively, in mice given 4 LD50 of toxin. The mouse model appears to be useful in studies on host resistance to anthrax and on the pathogenesis of the infection.
Animals↗
Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis.
The gene encoding the protective antigen (PA) moiety of the tripartite exotoxin of Bacillus anthracis was cloned from the recombinant plasmid pSE36 into Bacillus subtilis 1S53 by using the plasmid vector pUB110. Two clones, designated PA1 and PA2, were identified which produced PA in liquid cultures at levels of 20.5 to 41.9 micrograms/ml. This PA was identical to B. anthracis Sterne PA with respect to migration on sodium dodecyl sulfate-polyacrylamide gels and to Western blot antigenic reactivity. Addition of lethal factor or edema factor to PA1 and PA2 supernatants generated biologically active anthrax lethal toxin or edema-producing toxin, respectively. The recombinant plasmid in PA1 (pPA101) was 7.8 kilobases, whereas the PA2 strain plasmid (pPA102) was 6.1 kilobases. Both plasmids had deletions extending into the insert sequence but not into the DNA encoding the PA protein. Immunization with the live recombinant strains protected guinea pigs from lethal challenge with virulent B. anthracis spores, and the immunization partially or completely protected rats from intravenous challenge with anthrax lethal toxin.
Antigens, Bacterial↗
Experimental gastroenteritis in newly-hatched chicks infected with Campylobacter jejuni.
The susceptibility of chicks to enteritis caused by Campylobacter jejuni was studied. Three-day-old chicks did not develop enteritis after oral infection but chicks infected within 12 h of hatching developed gastroenteritis. The incubation period correlated with the inoculum size. Initially, infected chicks developed blood- and mucus-containing stools, although watery diarrhoea often occurred late in the course of the disease. Recurrences of the enteric manifestations were common but only two out of 170 infected chicks died. C. jejuni was recovered from sites throughout the intestine; the highest concentrations were present in the caecum and large intestine. Both the upper and lower gastrointestinal tract were affected and cellular infiltration of the gastric mucosa and the intestinal lamina propria was observed. Organisms resembling C. jejuni were seen within the intestinal epithelium and lamina propria by electronmicroscopy. The newly hatched chick provides a reproducible and sensitive model of campylobacter enteritis.
Animals↗
A modified broth-disk antibiotic susceptibility test for Campylobacter jejuni.
A broth-disk method for determining the antibiotic susceptibility of Campylobacter species was studied. The broth-disk method used to test anaerobes was modified for testing the antibiotic susceptibility of Campylobacter jejuni in an aerobic atmosphere. The basal medium of the test consisted of Brucella broth with 0.13% agar and contained a ferrous iron, sodium pyruvate, sodium bisufite supplement. Antibiotic disks were added to the tubed medium to approximate the minimal inhibitory concentration (MIC) breakpoint values for susceptibility. The antibiotic susceptibilities of 29 strains of Campylobacter jejuni to seven antibiotics were tested by the broth-disk method and the results compared with the MIC values determined by agar dilution. The broth-disk results were reproducible and agreed with approximately 90-100% of the MIC determinations. This broth-disk method appears to be a reliable, simple, and inexpensive method for testing antibiotic susceptibility of Campylobacter species.
Ampicillin↗